DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology

Chemistry and Biology

Volumn 20, Issue 5, 2013, Pages 648-659

  Cheung Ong, Kahlin ^a   Giaever, Guri ^b   Nislow, Corey ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DAUNORUBICIN; DNA; DOXORUBICIN; METHOTREXATE; OXALIPLATIN;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DNA DAMAGE; DROSOPHILA MELANOGASTER; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; GENETIC SCREENING; GENOMICS; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA; DNA DAMAGE; DRUG DISCOVERY; GENOMICS; HUMANS; NEOPLASMS;

EID: 84878235773     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.04.007     Document Type: Review

References (100)

1. S. Bandyopadhyay, M. Mehta, D. Kuo, M.K. Sung, R. Chuang, E.J. Jaehnig, B. Bodenmiller, K. Licon, W. Copeland, and M. Shales Rewiring of genetic networks in response to DNA damage Science 330 2010 1385 1389
2. H. Baruah, C.G. Barry, and U. Bierbach Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation Curr. Top. Med. Chem. 4 2004 1537 1549
3. R. Bernards, T.R. Brummelkamp, and R.L. Beijersbergen shRNA libraries and their use in cancer genetics Nat. Methods 3 2006 701 706
4. J.M. Berthiaume, and K.B. Wallace Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biol. Toxicol. 23 2007 15 25
5. J.R. Bertino, and B.N. Cronstein Methotrexate 2000 Birkhäuser Verlag Basel, Boston
6. G.W. Birrell, G. Giaever, A.M. Chu, R.W. Davis, and J.M. Brown A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity Proc. Natl. Acad. Sci. USA 98 2001 12608 12613
7. D. Botstein, S.A. Chervitz, and J.M. Cherry Yeast as a model organism Science 277 1997 1259 1260
8. K.J. Brennand, A. Simone, J. Jou, C. Gelboin-Burkhart, N. Tran, S. Sangar, Y. Li, Y. Mu, G. Chen, and D. Yu Modelling schizophrenia using human induced pluripotent stem cells Nature 473 2011 221 225
9. P.C. Bruijnincx, and P.J. Sadler New trends for metal complexes with anticancer activity Curr. Opin. Chem. Biol. 12 2008 197 206
10. D.J. Burgess, J. Doles, L. Zender, W. Xue, B. Ma, W.R. McCombie, G.J. Hannon, S.W. Lowe, and M.T. Hemann Topoisomerase levels determine chemotherapy response in vitro and in vivo Proc. Natl. Acad. Sci. USA 105 2008 9053 9058
11. J.E. Carette, C.P. Guimaraes, M. Varadarajan, A.S. Park, I. Wuethrich, A. Godarova, M. Kotecki, B.H. Cochran, E. Spooner, H.L. Ploegh, and T.R. Brummelkamp Haploid genetic screens in human cells identify host factors used by pathogens Science 326 2009 1231 1235
12. D. Carroll Genome engineering with zinc-finger nucleases Genetics 188 2011 773 782
13. C. Carvalho, R.X. Santos, S. Cardoso, S. Correia, P.J. Oliveira, M.S. Santos, and P.I. Moreira Doxorubicin: the good, the bad and the ugly effect Curr. Med. Chem. 16 2009 3267 3285
14. B.A. Chabner, and T.G. Roberts Jr. Timeline: Chemotherapy and the war on cancer Nat. Rev. Cancer 5 2005 65 72
15. M. Chang, M. Bellaoui, C. Boone, and G.W. Brown A genome-wide screen for methyl methanesulfonate-sensitive mutants reveals genes required for S phase progression in the presence of DNA damage Proc. Natl. Acad. Sci. USA 99 2002 16934 16939
16. G.L. Chen, L. Yang, T.C. Rowe, B.D. Halligan, K.M. Tewey, and L.F. Liu Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II J. Biol. Chem. 259 1984 13560 13566
17. K. Cheung-Ong, K.T. Song, Z. Ma, D. Shabtai, A.Y. Lee, D. Gallo, L.E. Heisler, G.W. Brown, U. Bierbach, G. Giaever, and C. Nislow Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents ACS Chem. Biol. 7 2012 1892 1901
18. M. Christian, T. Cermak, E.L. Doyle, C. Schmidt, F. Zhang, A. Hummel, A.J. Bogdanove, and D.F. Voytas Targeting DNA double-strand breaks with TAL effector nucleases Genetics 186 2010 757 761
19. T. Ciuleanu, M. Samarzjia, Y. Demidchik, V. Beliakouski, M. Rancic, D.L. Bentsion, S.V. Orlov, B.A. Schaeffler, R.L. De Jager, and H.B. Breitz Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy J. Clin. Oncol. 28 2010 15s
20. M. Costanzo, A. Baryshnikova, J. Bellay, Y. Kim, E.D. Spear, C.S. Sevier, H. Ding, J.L. Koh, K. Toufighi, and S. Mostafavi The genetic landscape of a cell Science 327 2010 425 431
21. S.M. Cutts, A. Nudelman, A. Rephaeli, and D.R. Phillips The power and potential of doxorubicin-DNA adducts IUBMB Life 57 2005 73 81
22. A.C. Dar, T.K. Das, K.M. Shokat, and R.L. Cagan Chemical genetic discovery of targets and anti-targets for cancer polypharmacology Nature 486 2012 80 84
23. A.R. David, and M.R. Zimmerman Cancer: an old disease, a new disease or something in between? Nat. Rev. Cancer 10 2010 728 733
24. G.P. Deshpande, J. Hayles, K.L. Hoe, D.U. Kim, H.O. Park, and E. Hartsuiker Screening a genome-wide S. pombe deletion library identifies novel genes and pathways involved in genome stability maintenance DNA Repair (Amst.) 8 2009 672 679
25. S. Farber Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer Blood 4 1949 160 167
26. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N. Engl. J. Med. 238 1948 787 793
27. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
28. P.L. Fischhaber, A.S. Gall, J.A. Duncan, and P.B. Hopkins Direct demonstration in synthetic oligonucleotides that N,N'-bis(2-chloroethyl)- nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA Cancer Res. 59 1999 4363 4368
29. S.L. Forsburg The yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe: models for cell biology research Gravit. Space Biol. Bull. 18 2005 3 9
30. S.J. Froelich-Ammon, and N. Osheroff Topoisomerase poisons: harnessing the dark side of enzyme mechanism J. Biol. Chem. 270 1995 21429 21432
31. V. Gagnon, M.E. St-Germain, C. Descôteaux, J. Provencher- Mandeville, S. Parent, S.K. Mandal, E. Asselin, and G. Bérubé Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies Bioorg. Med. Chem. Lett. 14 2004 5919 5924
32. G. Giaever, D.D. Shoemaker, T.W. Jones, H. Liang, E.A. Winzeler, A. Astromoff, and R.W. Davis Genomic profiling of drug sensitivities via induced haploinsufficiency Nat. Genet. 21 1999 278 283
33. G. Giaever, A.M. Chu, L. Ni, C. Connelly, L. Riles, S. Véronneau, S. Dow, A. Lucau-Danila, K. Anderson, and B. André Functional profiling of the Saccharomyces cerevisiae genome Nature 418 2002 387 391
34. G. Giaever, P. Flaherty, J. Kumm, M. Proctor, C. Nislow, D.F. Jaramillo, A.M. Chu, M.I. Jordan, A.P. Arkin, and R.W. Davis Chemogenomic profiling: identifying the functional interactions of small molecules in yeast Proc. Natl. Acad. Sci. USA 101 2004 793 798
35. A. Gilman The initial clinical trial of nitrogen mustard Am. J. Surg. 105 1963 574 578
36. A. Gilman, and F.S. Philips The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides Science 103 1946 409 436
37. M. Gladstone, and T.T. Su Chemical genetics and drug screening in Drosophila cancer models J. Genet. Genomics 38 2011 497 504
38. L.S. Goodman, M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman, and M.T. McLennan Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders J. Am. Med. Assoc. 132 1946 126 132
39. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
40. T.W. Hambley The influence of structure on the activity and toxicity of Pt anti-cancer drugs Coord. Chem. Rev. 166 1997 181 223
41. G.J. Hannon RNA interference Nature 418 2002 244 251
42. J. Heitman, N.R. Movva, and M.N. Hall Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 1991 905 909
43. R.P. Hertzberg, M.J. Caranfa, and S.M. Hecht On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex Biochemistry 28 1989 4629 4638
44. M.E. Hillenmeyer, E. Fung, J. Wildenhain, S.E. Pierce, S. Hoon, W. Lee, M. Proctor, R.P. St Onge, M. Tyers, and D. Koller The chemical genomic portrait of yeast: uncovering a phenotype for all genes Science 320 2008 362 365
45. J. Holford, S.Y. Sharp, B.A. Murrer, M. Abrams, and L.R. Kelland In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473 Br. J. Cancer 77 1998 366 373
46. S. Hoon, A.M. Smith, I.M. Wallace, S. Suresh, M. Miranda, E. Fung, M. Proctor, K.M. Shokat, C. Zhang, and R.W. Davis An integrated platform of genomic assays reveals small-molecule bioactivities Nat. Chem. Biol. 4 2008 498 506
47. A.L. Hopkins, and C.R. Groom The druggable genome Nat. Rev. Drug Discov. 1 2002 727 730
48. Y.H. Hsiang, R. Hertzberg, S. Hecht, and L.F. Liu Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 260 1985 14873 14878
49. H. Huang, L. Zhu, B.R. Reid, G.P. Drobny, and P.B. Hopkins Solution structure of a cisplatin-induced DNA interstrand cross-link Science 270 1995 1842 1845
50. X. Huang, A.T. Nguyen, Z. Li, A. Emelyanov, S. Parinov, and Z. Gong One step forward: the use of transgenic zebrafish tumor model in drug screens Birth Defects Res. C Embryo Today 93 2011 173 181
51. Y. Kalender, M. Yel, and S. Kalender Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin Toxicology 209 2005 39 45
52. L. Kapitzky, P. Beltrao, T.J. Berens, N. Gassner, C. Zhou, A. Wüster, J. Wu, M.M. Babu, S.J. Elledge, and D. Toczyski Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action Mol. Syst. Biol. 6 2010 451
53. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 2007 573 584
54. T. Ketela, L.E. Heisler, K.R. Brown, R. Ammar, D. Kasimer, A. Surendra, E. Ericson, K. Blakely, D. Karamboulas, and A.M. Smith A comprehensive platform for highly multiplexed mammalian functional genetic screens BMC Genomics 12 2011 213
55. D.U. Kim, J. Hayles, D. Kim, V. Wood, H.O. Park, M. Won, H.S. Yoo, T. Duhig, M. Nam, and G. Palmer Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe Nat. Biotechnol. 28 2010 617 623
56. P. Köpf-Maier Complexes of metals other than platinum as antitumour agents Eur. J. Clin. Pharmacol. 47 1994 1 16
57. E.B. Krumbhaar, and H.D. Krumbhaar The blood and bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases J. Med. Res. 40 1919 497 508
58. W. Lee, R.P. St Onge, M. Proctor, P. Flaherty, M.I. Jordan, A.P. Arkin, R.W. Davis, C. Nislow, and G. Giaever Genome-wide requirements for resistance to functionally distinct DNA-damaging agents PLoS Genet. 1 2005 e24
59. M.C. Li, R. Hertz, and D.M. Bergenstal Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists N. Engl. J. Med. 259 1958 66 74
60. P.Y. Lum, C.D. Armour, S.B. Stepaniants, G. Cavet, M.K. Wolf, J.S. Butler, J.C. Hinshaw, P. Garnier, G.D. Prestwich, and A. Leonardson Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes Cell 116 2004 121 137
61. B. Luo, H.W. Cheung, A. Subramanian, T. Sharifnia, M. Okamoto, X. Yang, G. Hinkle, J.S. Boehm, R. Beroukhim, and B.A. Weir Highly parallel identification of essential genes in cancer cells Proc. Natl. Acad. Sci. USA 105 2008 20380 20385
62. J. Luo, M.J. Emanuele, D. Li, C.J. Creighton, M.R. Schlabach, T.F. Westbrook, K.K. Wong, and S.J. Elledge A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
63. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
64. J. Moffat, D.A. Grueneberg, X. Yang, S.Y. Kim, A.M. Kloepfer, G. Hinkle, B. Piqani, T.M. Eisenhaure, B. Luo, and J.K. Grenier A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen Cell 124 2006 1283 1298
65. B.C. O'Connell, B. Adamson, J.R. Lydeard, M.E. Sowa, A. Ciccia, A.L. Bredemeyer, M. Schlabach, S.P. Gygi, S.J. Elledge, and J.W. Harper A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability Mol. Cell 40 2010 645 657
66. L. O'Donnell, S. Panier, J. Wildenhain, J.M. Tkach, A. Al-Hakim, M.C. Landry, C. Escribano-Diaz, R.K. Szilard, J.T. Young, and M. Munro The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination Mol. Cell 40 2010 619 631
67. A. Olivi, M. Gilbert, K.L. Duncan, B. Corden, D. Lenartz, and H. Brem Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study Cancer Chemother. Pharmacol. 31 1993 449 454
68. R.D. Olson, and P.S. Mushlin Doxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J. 4 1990 3076 3086
69. A. Olson, N. Sheth, J.S. Lee, G. Hannon, and R. Sachidanandam RNAi Codex: a portal/database for short-hairpin RNA (shRNA) gene-silencing constructs Nucleic Acids Res. 34 Database issue 2006 D153 D157
70. T.F. Outeiro, and S. Lindquist Yeast cells provide insight into alpha-synuclein biology and pathobiology Science 302 2003 1772 1775
71. X. Pan, B. Lei, N. Zhou, B. Feng, W. Yao, X. Zhao, Y. Yu, and H. Lu Identification of novel genes involved in DNA damage response by screening a genome-wide Schizosaccharomyces pombe deletion library BMC Genomics 13 2012 662
72. W.B. Parker, and Y.C. Cheng Metabolism and mechanism of action of 5-fluorouracil Pharmacol. Ther. 48 1990 381 395
73. S.E. Pierce, E.L. Fung, D.F. Jaramillo, A.M. Chu, R.W. Davis, C. Nislow, and G. Giaever A unique and universal molecular barcode array Nat. Methods 3 2006 601 603
74. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol. Cancer Ther. 1 2002 227 235
75. O. Rixe, W. Ortuzar, M. Alvarez, R. Parker, E. Reed, K. Paull, and T. Fojo Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem. Pharmacol. 52 1996 1855 1865
76. B. Rosenberg, L. Vancamp, and T. Krigas Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode Nature 205 1965 698 699
77. M. Sawicka, M. Kalinowska, J. Skierski, and W. Lewandowski A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence J. Pharm. Pharmacol. 56 2004 1067 1081
78. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
79. T. Simůnek, M. Stérba, O. Popelová, M. Adamcová, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol. Rep. 61 2009 154 171
80. A.M. Smith, L.E. Heisler, J. Mellor, F. Kaper, M.J. Thompson, M. Chee, F.P. Roth, G. Giaever, and C. Nislow Quantitative phenotyping via deep barcode sequencing Genome Res. 19 2009 1836 1842
81. A. Smogorzewska, R. Desetty, T.T. Saito, M. Schlabach, F.P. Lach, M.E. Sowa, A.B. Clark, T.A. Kunkel, J.W. Harper, M.P. Colaiácovo, and S.J. Elledge A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair Mol. Cell 39 2010 36 47
82. R.P. St Onge, R. Mani, J. Oh, M. Proctor, E. Fung, R.W. Davis, C. Nislow, F.P. Roth, and G. Giaever Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions Nat. Genet. 39 2007 199 206
83. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
84. P.M. Takahara, A.C. Rosenzweig, C.A. Frederick, and S.J. Lippard Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin Nature 377 1995 649 652
85. J. Tangpong, M.P. Cole, R. Sultana, G. Joshi, S. Estus, M. Vore, W. St Clair, S. Ratanachaiyavong, D.K. St Clair, and D.A. Butterfield Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity Neurobiol. Dis. 23 2006 127 139
86. E.W. Taylor The Mechanism of Colchicine Inhibition of Mitosis. I. Kinetics of Inhibition and the Binding of H3-Colchicine J. Cell Biol. 25 SUPPL 1965 145 160
87. J.M. Tkach, A. Yimit, A.Y. Lee, M. Riffle, M. Costanzo, D. Jaschob, J.A. Hendry, J. Ou, J. Moffat, and C. Boone Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stress Nat. Cell Biol. 14 2012 966 976
88. I.M. Wallace, M.L. Urbanus, G.M. Luciani, A.R. Burns, M.K. Han, H. Wang, K. Arora, L.E. Heisler, M. Proctor, and R.P. St Onge Compound prioritization methods increase rates of chemical probe discovery in model organisms Chem. Biol. 18 2011 1273 1283
89. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320
90. N.J. Wheate, S. Walker, G.E. Craig, and R. Oun The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 39 2010 8113 8127
91. L.F. Willoughby, T. Schlosser, S.A. Manning, J.P. Parisot, I.P. Street, H.E. Richardson, P.O. Humbert, and A.M. Brumby An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery Dis. Model. Mech. 6 2013 521 529
92. L. Wills, P.W. Clutterbuck, and B.D. Evans A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia Biochem. J. 31 1937 2136 2147
93. E.A. Winzeler, D.D. Shoemaker, A. Astromoff, H. Liang, K. Anderson, B. Andre, R. Bangham, R. Benito, J.D. Boeke, and H. Bussey Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis Science 285 1999 901 906
94. C.T. Workman, H.C. Mak, S. McCuine, J.B. Tagne, M. Agarwal, O. Ozier, T.J. Begley, L.D. Samson, and T. Ideker A systems approach to mapping DNA damage response pathways Science 312 2006 1054 1059
95. World Health Organization (2012). Cancer Fact Sheet. http://www.who.int/ mediacentre/factsheets/fs297/en/index.html.
96. A.J. Wozniak, and W.E. Ross DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity Cancer Res. 43 1983 120 124
97. J. Xiang, H. Yang, C. Che, H. Zou, H. Yang, Y. Wei, J. Quan, H. Zhang, Z. Yang, and S. Lin Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays PLoS ONE 4 2009 e4361
98. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124
99. J.R. Yeh, K.M. Munson, Y.L. Chao, Q.P. Peterson, C.A. Macrae, and R.T. Peterson AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression Development 135 2008 401 410
100. F. Zunino, G. Savi, and A. Pasini Synthesis and antitumor activity of a platinum (II)-doxorubicin complex Cancer Chemother. Pharmacol. 18 1986 180 182